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T. marneffei causes a deadly systemic infection in immunocompromised hosts 2, 3 . The rapid rise in T. marneffei infections associated with the worldwide HIV pandemic led to it being described as an AIDS-defining pathogen 3 . While there are sporadic reports of T. marneffei infections in 'immunocompetent hosts' the immune status has not been adequately tested in these cases, and the term 'immunocompetent' is often used interchangeably (and incorrectly) in these reports with HIV negative status. The ecological niche of T. marneffei is unclear, but there is a strong association with a number of bamboo rat species in endemic areas 3, 4 .
T. marneffei is unique as the only member of the very large
Eurotiales order that can undergo a dimorphic switch, and the only 'Penicillium' species within this order known to be a pathogen 5, 6 .
Under the Microscope
As for many dimorphic pathogens, temperature is a key trigger for the dimorphic transition ( Figure 1 Genetics studies in T. marneffei aimed at dissecting the roles of cell signalling and polarity determinants have identified many highly conserved factors including p21-activated kinases (PAKs) and Rassuperfamily small GTPases (Ras/Rho/Cdc42/Rac) 7, 8 . In T. marneffei,
PAKs are key regulators of the temperature-dependent response.
Mutants in pakA fail to germinate at 378C either in vitro or in host 
Future directions
Despite the efforts of many groups around the world, working on a range of dimorphic fungal pathogens, studies into the mechanisms that control this morphogenetic transition, which is central to pathogenicity, are in their infancy. A handful of key factors have been identified and these are excellent entry points into uncovering the network of genes that regulate this process. With the newly developed high-throughput genomic tools such as ChIP-seq that are now available and established in these various dimorphic pathogens, our understanding of these systems is primed to uncover new and exciting avenues for the control and treatment of these infections.
